A study to describe utilization and characteristics of patients receiving Infliximab and its biosimilars in US community rheumatology practices
Latest Information Update: 18 Jan 2021
At a glance
- Drugs Infliximab (Primary) ; Infliximab (Primary) ; Infliximab (Primary) ; Infliximab biobetter (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
Most Recent Events
- 18 Jan 2021 New trial record